YAMAHA
12.5.2023 04:01:33 CEST | Business Wire | Press release
In cooperation with the Delhi Board of School Education, Yamaha Corporation (below, "Yamaha") introduced Japanese-style instrumental music education using recorders for grade V students at ten public primary schools in India in April. Programs using recorders and keyboards have been offered as extra-curriculum activities at private primary schools in India since 2017, but this is the first time a program will be offered as part of public primary school classes. The program offered by Yamaha not only includes technical recorder instruction, but also incorporates groupwork and discussion within classes to cultivate mutual understanding. Preceding the start of the classes, music teacher training is being conducted with an emphasis on using a holistic learning approach. Yamaha aims to expand the program to more schools in Delhi in the future. “Introduction of Japanese-style music education in primary education in India” was adopted by MEXT as a 2022 EDU-Port Japan*1 Supported Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005424/en/
Classes at public primary school in India
About School Project
As a comprehensive musical instruments manufacturer, Yamaha has been promoting the advantages of music and instrumental music education to music education sites around the world. In particular, Yamaha’s School Project, which it has been developing principally in emerging countries since 2015, is an initiative with the aim of popularizing activities using music and musical instruments in public education to convey the joy of music and musical instruments. To date, Yamaha has provided a total of 2,020,000 children (as of March 2023) in seven countries—Malaysia, Indonesia, Vietnam, India, Brazil, the United Arab Emirates, and Egypt—with opportunities to learn instrumental music, helping to create an environment where children can enjoy music and playing musical instruments.
Through this activity, Yamaha aims to contribute to Goal 4: "Quality Education," Goal 10: “Reduced Inequalities,” Goal 16: “Peace, Justice and Strong Institutions,” and Goal 17: "Partnerships for the Goals" of the Sustainable Development Goals (SDGs), as well as to develop children's non-cognitive skills through music and instrumental music education and to formulate a business model for musical education activities tailored to the educational situation in schools around the world.
Comments from Yasuhiro Yonehara, First Secretary, Embassy of Japan in India
Walking through the streets of India, one can hear music along with the bustling of the city. In Bollywood films, actors can be seen dancing joyfully to upbeat songs. Indian people are very familiar with music, and I feel that music is an integral part of their lives. How exciting it is when Indian children pick up a recorder, an unfamiliar instrument, learn to play it and create music. I sincerely wish that this initiative, which is making this possible, will be a huge success.
*1 EDU-Port Japan is a “public-private, nationwide” initiative to introduce Japanese-style education overseas using the public-private collaborative platform, supported by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT).
https://www.yamaha.com/en/about/activities/school_project/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005424/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
